News
08.10.2020

Cromos Pharma and Avance Clinical launch scalable clinical trial solution for biotech

Dublin/Ireland – Adelaide/Australia – Two dominant regional contract research organizations (CRO), Avance Clinical and Cromos Pharma, with operations in Australia and Central/Eastern Europe, respectively, are successfully collaborating on a scalable clinical solution for biotechs.

The collaboration allows biotechs to quickly start their pre-IND early phase studies in Australia, then expand to Central/Eastern Europe to access the large patient populations for their Phase 2 and 3 studies.

Importantly, the AU/EU model allows biotechs to keep their data and trial management in Australia, and take advantage of the Australian cash rebate of up to 43.5% on clinical trial costs, throughout all study phases, across both regions.

1.png

“We are very excited about this model that seamlessly incorporates two of the most compelling and complementary international clinical research hubs for our biotech clients from early to late phase studies,” said Yvonne Lungershausen, CEO of Avance Clinical. “Our eClinical and early phase expertise is well augmented by Cromos Pharma’s track record in late stage trials and rapid enrollment capabilities,” she continued.

“We have been collaborating with Avance Clinical and referring clients to each other for years,” remarked Vlad Bogin, CEO of Cromos Pharma. “But it was a true Eureka moment when we realized that combining Australia’s 43.5% tax rebate with Central/Eastern Europe’s unbeatable recruitment rates is a paradigm shift in how clinical trials should be conducted,” he concluded.

Cromos Pharma can access hundreds of millions of patients via more than 2,500 sites in Central/Eastern Europe.

WATCH OUR VIDEO HERE

About Cromos Pharma www.cromospharma.com

Cromos Pharma provides tailored and effective clinical trial solutions to support the development of drugs that transform healthcare. An international CRO with over 15 years’ experience, we offer fully integrated services performing all aspects of clinical trials in all clinical phases and in a wide range of therapeutic areas. Cromos Pharma delivers rapid recruitment and excellent patient retention as well as expert study design and management. Cromos Pharma has strong regional experience in Central and Eastern Europe with global coverage provided by its US bases in Portland, Oregon and Miami, Florida. Cromos Pharma’s European HQ is in Dublin, Ireland. At Cromos Pharma, we know how important your product is. When the stakes are this high, you need a high-performance partner. 

Key benefits:

  • International expertise combined with in-depth regional knowledge in Central and Eastern Europe (300+ clinical trials conducted in 70+ indications). 
  • Extensive PI/site and patient network (40,000+ patients enrolled from nearly 2,500 trial sites).
  • Unparalleled patient recruitment – our team met or shortened project timelines in 95% of conducted trials.
  • Responsible recruitment is supported by Cromos Pharma’s “No Patients-No Payments” initiative – a unique risk-sharing program. 
  • Extremely short startup timelines (e.g. Georgia where we assure a study launch in less than 2 months).
  • Expertise in innovative, generics and biosimilar global studies (NDAs, ANDAs, BLAs, 505b2).
  • Regulatory inspections and audits that attest to the highest quality of data: EMA in 2019 (1-week oncology site inspection); FDA in 2017 (2-week oncology site inspection).
  • Clinical Development Strategy – we provide expert guidance on study design, favorable venues, local and global landscape to improve study outcomes.

About Avance Clinical www.avancecro.com 

Australia’s Avance Clinical has more than 20-years of experience and is now one of Australia’s leading Contract Research Organizations for biotechs. Avance Clinical is committed to providing high-quality clinical research services with its highly-experienced team.
The collective pool of knowledge and experience at Avance Clinical continually grows through the careful selection of experts who also demonstrate passion in their chosen field.
Avance Clinical offers high-quality services in an established clinical trial ecosystem, that includes world-class Investigators and Sites able to access specialized patient groups. 

Other benefits include:
1. The Government R&D grant means up to 43.5% rebate on clinical trial spend
2. eClinical solutions capabilities – speed and continuity
3. Site Initiation Visit (SIV) and Study Start achieved in 5 – 6 weeks
4. No IND required for clinical trials
5. Full GMP material is not mandated for Phase I clinical trials
6. Established clinical trial environment with world-class Investigators and sites
7. Established healthy subject databases and specialized patient populations
8. Five independent Phase 1 facilities across Australia including hospital-based units for critical care
9. Major hospitals with world-class infrastructures and dedicated Clinical Trial Units with a long track-record in FDA compliant research
10. Seasonal studies: Northern hemisphere Sponsors can conduct their studies year-round by taking advantage of Australia’s counter-flu and allergy seasons

Media Contacts: 

Avance Clinical 

Chris Thompson: media@avancecro.com

Cromos Pharma

Nicola Donnelly: media@cromospharma.com



Other News:
news

Watch Webinar: Where in the world should I locate my pivotal clinical trial?

If you missed the live webinar “Where in the world should I locate my pivotal clinical trial?” you can now watch the recording by clicking hereThe webinar hosted by the Society of Physician Entrepreneurs (SoPE) and Workforce Genetics features Cromos Pharma's CEO Vlad Bogin, M.D, FACP. 


24.09.2020
news

Watch our video: Navigating an era of uncertainty

We are pleased to share with you our new video Cromos Pharma: Helping to navigate an era of uncertainty.

02.09.2020
news

Webinar: Where in the world should I locate my pivotal clinical trial?

01.09.2020
news

EU cancer estimates for 2020 reveal 2.7 million new cases

The European Joint Research Council released its 2020 burden of cancer estimates on 22 July, 2020. The report revealed The cancer burden is estimated to have risen to 2.7 million new cases (all types, excluding non-melanoma skin cancer) and 1.3 million deaths in 2020. Female breast cancer remains the most commonly diagnosed.
26.07.2020
news

FDA proposes new rule on reporting requirements to support Right to Try

On July 23, the U.S. Food and Drug Administration (FDA) announced a new proposed rule that would require sponsors and manufacturers who provide an ‘‘eligible investigational drug’’ under the Right to Try Act to submit an annual summary of such use to FDA.
26.07.2020
news

European medicines agencies launch public consultation on joint strategy

The European Medicines Agency (EMA) and the Heads of Medicines Agencies (HMA) have developed a joint strategy for the next five years. It was released for a two-month public consultation period on 6, July, 2020.
14.07.2020
news

Two new reports find impacts of COVID-19 on clinical trials easing slightly

Two new reports released by GlobalData Healthcare and Medidata find evidence of COVID-19 impacts on clinical trials easing slightly. 
13.07.2020
news

Risk Based Monitoring- a data-centric approach to monitoring

In this Insights@CromosPharma article our Chief Operating Officer Stephanie Finnegan explores the role of Risk Based Monitoring (RBM) in clinical trials, how it has been utilized in response to the current coronavirus pandemic, and how the experience may shape the industry's approach to RBM in the future.
30.06.2020
news

Cromos Pharma Recruits over 300 Patients in Under Two Months into a COVID-19 Clinical Trial

Cromos Pharma, an international CRO, is pleased to announce unprecedented recruitment in a phase IIb trial in patients with moderate to severe COVID-19 infection.
18.06.2020
news

Connect with Cromos Pharma at BIO Digital 2020

Cromos Pharma is delighted to be participating in BIO Digital 2020, June 8-12 2020. 
02.06.2020
news

Cromos Pharma celebrates International Clinical Trials Day 2020

Today (20 May, 2020) marks International Clinical Trials Day 2020. Cromos Pharma wishes to express its gratitude to everyone who participates in  and conducts clinical trials that help turn research into reality and make lifesaving and life-changing medical treatments available to patients all over the world.
20.05.2020
news

First patients enrolled in Cromos Pharma managed Covid-19 trial

Cromos Pharma is proud to be part of the global search for effective COVID-19 treatments. Today (24 April, 2020) we are pleased to announce the enrollment of the first patients in clinical trials designed to be find drugs to treat the symptoms of coronavirus.
27.04.2020
news

Cromos Pharma insights on master protocols

Master protocols are disrupting the clinical trial space by offering a more comprehensive and adaptive approach to studying treatments for the most complex of diseases. Cromos Pharma is delighted to share with you a recently published article on the topic by CEO Dr Vlad Bogin.
27.04.2020
news

Cromos Pharma supporting World Immunization Week

Vaccines are some of our most powerful weapons against deadly diseases. Cromos Pharma salutes all those involved in the development, administration and promotion of vaccines all over the world.
23.04.2020
news

Cromos Pharma wishes you a safe and healthy Easter and Passover

At the most difficult time, the entire Cromos Pharma Team wishes all our patients, clients, investigators, site personnel and partners a safe and healthy Easter and Passover.
10.04.2020
news

European Medicines Agency launches new regulatory science strategy

The European Medicines Agency (EMA) recently (31 March 2020) published its Regulatory Science Strategy to 2025. The strategy provides a plan for advancing regulatory science over the next five years, covering both human and veterinary medicines.
08.04.2020
news

Cromos Pharma to run COVID-19 trial

Cromos Pharma is pleased to announce that it has been enlisted to run a clinical trial of a repurposed drug candidate to treat COVID-19.  
01.04.2020
news

Cromos Pharma committed to delivering in the face of COVID-19 challenges

Cromos Pharma has been closely following the COVID-19 outbreak as it continues to spread across the globe.
13.03.2020
news

Cromos Pharma launches new series to explore the latest developments in clinical trials sector

2020 marks the start of a new decade when we can anticipate several trends to take hold in the global clinical research market. What can we expect in terms of the market in terms of growth and trends? Throughout 2020 Cromos Pharma’s team of experts will look at some of the major trends dominating the current market and future influences on clinical research.
09.03.2020
news

Celebrating the Women of Cromos Pharma on IWD 2020

On the occasion of International Women’s Day (8 March 2020) we at Cromos Pharma are celebrating the enormous contribution of our female team members.
08.03.2020
news

Cromos Pharma launches a new office in Warsaw, Poland

Cromos Pharma, an international provider of clinical trial and drug development services, today (04 MARCH 2020) announced the opening of its new office in Warsaw, Poland. The opening of the new office strengthens Cromos Pharma’s position in Poland where it has been operational since 2015.

“The establishment of the Poland office is a major development in line with Cromos Pharma’s continued expansion in European and US operations marking another milestone in the sustained growth of the Company. Poland is a significant clinical trials market that has many advantages making it highly attractive to international sponsors,” said Dr. Vlad Bogin, CEO, Cromos Pharma, “Cromos Pharma looks forward to offering sponsors an extended range of our expert services through its new office to ensure effective and cost-efficient execution of clinical trials”.

With its 40 million people Poland is one of the largest clinical trials markets in Eastern Europe that has a strong track record of over 20 years in delivering high-quality research. It boasts several advantages including a large naïve population and well-developed research infrastructure. Polish patients are positively disposed to taking part in clinical trials as it offers them an opportunity to access innovative treatments otherwise not always available to them. The country has a large network of highly skilled and motivated clinical investigators and medical professionals keen to participate in clinical research. Poland also offers relatively low costs and excellent patient recruitment.

With excellent rates of patient recruitment, high-quality data, highly skilled and committed investigators, and comparatively low costs, Poland is an attractive location for sponsors. Cromos Pharma is ready to help you access these advantages through our excellent knowledge of the regulatory processes and our existing relationships with sites and investigators.

Learn more about conducting clinical trials in Poland with Cromos Pharma here.

To explore these advantages and the services Cromos Pharma can offer you please email bd@cromospharma.com.

About Cromos Pharma

Cromos Pharma is an international Contract Research Organization (CRO) providing tailored and effective clinical trials management to support the development of drugs that transform healthcare. It offers fully integrated services with expertise in all aspects of clinical trials of all phases in a wide range of therapeutic indications. Cromos Pharma delivers rapid recruitment and excellent patient retention as well as expert study design and management. Cromos Pharma has an extensive network of offices across 15 countries and strong regional experience in Central and Eastern Europe. Its European HQ is situated in Dublin, Ireland and its US base is in Portland, Oregon with an operational base in South Florida.
04.03.2020
news

Cromos Pharma attends Asia Matters briefing

21.01.2020
news

Thank you for your business and support throughout 2019. We look forward to working with you in 2020!

On behalf of everyone at Cromos Pharma I would like to wish our clients and partners a very happy and healthy holiday season. Thank you for your business and support throughout 2019. We look forward to working with you in 2020!
17.12.2019
news

Meet Cromos Pharma’s CEO at the 38th Annual J.P Morgan Healthcare Conference

09.12.2019
news

Meet Cromos Pharma at 61st ASH Annual Meeting & Exposition

29.11.2019
news

Thanksgiving Message

27.11.2019
news

Our medical writing team is focused on delivering the results you need.

31.10.2019
news

Cromos Pharma celebrating 15 years of excellence in clinical research

24.10.2019
news

Join us at ESMO in Barcelona on September 27 - October 1, 2019

19.09.2019
news

Meet us at Outsourcing in Clinical Trials Pacific Northwest in Seattle on October 16 - 17 2019

19.09.2019
news

Meet the Cromos Pharma team at the 2019 KoNECT-MOHW-MFDS International Conference to be held on September 17 – 19 in Seoul, South Korea.

30.08.2019
news

Cromos Pharma CEO highlights opportunities and challenges for small sponsors at MAGI Clinical Research Conference

20.08.2019
news

Cromos Pharma sets a new record in site initiation timelines in Poland

15.08.2019
news

Cromos Pharma's "Your Perfect CRO" Survey shows surprising results

24.07.2019
news

Cromos Pharma recruits 473 patients (92% of total) into a breast cancer trial, all in under 7 months.

17.06.2019